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Abstract
A substantial proportion of atrial fibrillation patients initiating direct oral anticoagu-
lants (DOAC) are vitamin K antagonists (VKA)‐experienced, for example switchers 
from VKA to DOAC. With this study, we aimed to summarize available evidence on 
the effectiveness and safety of DOAC vs VKA in real‐life VKA‐experienced atrial 
fibrillation patients. We searched EMBASE, MEDLINE and Cochrane Library sys-
tematically for English‐language studies indexed any time before October 2018. We 
included studies of VKA‐experienced atrial fibrillation patients initiating DOAC 
therapy, with continued VKA therapy as comparator. Outcomes included arterial 
thromboembolism and bleeding. When appropriate, meta‐analysis was performed by 
calculating pooled, weighted and adjusted hazard ratios (aHR) with 95% confidence 
intervals (CI). Eight cohort studies comparing VKA‐experienced DOAC (dabigatran 
or rivaroxaban) users with continued VKA users were included. When comparing 
DOAC to VKA, an increased risk of ischaemic stroke and myocardial infarction 
was found for dabigatran (pooled aHR of 1.61 [95% CI 1.19‐2.19, I2 = 65%] and 
1.29 [95% CI 1.10‐1.52, I2 = 0%], respectively), but not for rivaroxaban. The use 
of dabigatran in VKA‐experienced users was associated with an increased risk of 
gastrointestinal bleeding (pooled aHR 1.63 [95% CI 1.36‐1.94, I2 = 30%]), but a de-
creased risk of intracranial bleeding (pooled aHR 0.45 [95% CI 0.32‐0.64, I2 = 0%]). 
In conclusion, the use of dabigatran in prior VKA users in clinical practice was asso-
ciated with a slightly increased risk of arterial thromboembolism and gastrointestinal 
bleeding, but a decreased risk of intracranial bleeding. Importantly, observational 
studies of real‐life VKA‐experienced oral anticoagulant users may be confounded by 
the reason for switching.
K E Y W O R D S
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1 |  INTRODUCTION
Direct oral anticoagulants (DOAC: dabigatran, rivaroxaban, 
apixaban and edoxaban) were introduced from 2010 and 
onwards as alternatives to vitamin K antagonists (VKA, eg 
warfarin) for stroke prevention in patients with atrial fibril-
lation (AF). In four large randomized clinical trials (RCT),1-4 
DOACs were equally or more effective to warfarin while con-
ferring a similar or lower risk of bleeding. As DOACs also 
provide a more convenient therapy, their use has rapidly in-
creased in AF patients.5,6 A substantial proportion of AF pa-
tients initiating DOAC therapy are previous VKA users and 
thereby not naïve to oral anticoagulant therapy.7 The majority 
of these ‘VKA‐experienced’ DOAC users are ongoing VKA 
users switching to DOAC therapy.
Evidence from RCTs on the efficacy of DOACs in pa-
tients previously exposed to VKA is conflicting. For dabiga-
tran, rivaroxaban and apixaban, the treatment effect relative 
to warfarin did not differ between VKA‐naïve and VKA‐ex-
perienced patients.8-10 In contrast, while edoxaban showed 
superior efficacy to warfarin in VKA‐naïve trial participants 
in the ENGAGE AF trial, VKA‐experienced participants had 
no benefit of edoxaban relative to warfarin with regard to the 
risk of ischaemic stroke and systemic embolism.11 Also, the 
two RCTs comparing the thrombin inhibitor ximelagatran to 
warfarin in AF patients differed in the number of VKA‐ex-
perienced trial participants included.12,13 Consequently, the 
trials reached different conclusions regarding the relative ef-
ficacy; the trial with the highest number of VKA‐experienced 
trial participants showed the lowest benefit of ximelagatran 
relative to warfarin.14
The benefits of DOACs vs. warfarin demonstrated in RCTs 15 
have been confirmed in several large cohorts of real‐life new 
users of oral anticoagulants.16,17 However, compared to such 
VKA‐naïve oral anticoagulant initiators, VKA‐experienced ini-
tiators, including switchers from VKA to DOAC, have already 
‘survived’ the risks associated with being exposed to AF as well 
as anticoagulation for the first time.18,19 The fact that they are 
still eligible for oral anticoagulant therapy may influence the 
treatment benefit of DOACs vs VKA in clinical trials as well 
as in clinical practice. Based on an overall aim of exploring 
the potential risks and benefits associated with switching from 
VKA to DOAC, the objective of this systematic review and 
meta‐analysis was to summarize current evidence concerning 
the comparative effectiveness and safety of DOACs vs VKA in 
VKA‐experienced real‐life anticoagulant users with AF.
2 |  MATERIAL AND METHODS
This systematic review and meta‐analysis is reported ac-
cording to the ‘Meta‐analyses of Observational Studies in 
Epidemiology’ (MOOSE) reporting guidelines.20
2.1 | Data sources and searches
Based on search terms indicating (a) AF, (b) treatment with 
DOAC, (c) treatment with VKA and (d) drug switching, we 
performed a systematic search in electronic bibliographic 
databases, including MEDLINE, EMBASE and Cochrane 
Library's Database of Systematic Reviews. As we aimed 
for a high sensitivity, only one further restriction—English‐
language studies—was applied to the literature search. We 
searched for studies indexed any time before 15 October 
2018. The literature search was performed by one reviewer 
(MH) and planned in collaboration with and supervised by a 
health science librarian. The detailed search strategy is pro-
vided in Table S1. Further, we hand‐searched reference lists 
of relevant reviews identified in the search.
2.2 | Study selection
Using Covidence, titles and abstracts of articles containing 
all four types of search terms were screened by two inde-
pendent reviewers (MH and KA). Full text was obtained and 
screened for all abstracts that appeared to meet the eligibil-
ity criteria. Studies on AF patients were considered eligible 
if they compared the risk of outcomes in VKA‐experienced 
DOAC initiators to the risk in patients continuing VKA 
treatment (‘VKA‐experienced VKA users’). Outcomes in-
cluded arterial thromboembolic events (myocardial infarc-
tion and ischaemic stroke ± transient ischaemic attack and/
or systemic embolism), specific and non‐specific bleeding 
events (gastrointestinal bleeding, intracranial bleeding and 
any bleeding), and all‐cause mortality. Thus, an eligible 
study could be a study comparing the risk of ischaemic 
stroke in AF patients who switched from VKA to DOAC 
to the risk in AF patients who remained on VKA therapy. 
To avoid inclusion of results potentially biased by immortal 
time,21 we required that switchers had been followed from 
the date of the switch in potentially eligible cohort studies. 
We only included peer‐reviewed original work. Differences 
in eligibility assessment of studies were resolved by consen-
sus among the reviewers.
2.3 | Data extraction and quality assessment
Data extraction was performed independently by two review-
ers. Using a standardized data collection form, we collected 
data on relevant study characteristics, study population and 
the clinical outcomes of interest. Any data discrepancy was 
resolved by referring to the original study.
To evaluate the risk of bias in the included studies, we 
used ‘the Newcastle‐Ottawa Scale for assessing the quality of 
non‐randomized studies’ modified to fit this specific meta‐
analysis (Table S2). In observational cohort studies, this 
scale evaluates cohort selection (four items), comparability 
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of cohorts (two items) and outcome assessment (three items) 
by assigning points to each category.22 For each category, a 
maximum of one point per item can be assigned, yielding a 
point maximum of nine. A high number of points indicate a 
low risk of bias. The quality assessment was also performed 
independently by two assessors. Any disagreement was re-
solved by consensus.
2.4 | Data synthesis
Results for each of the outcomes of interest were strati-
fied by type of DOAC initiated and summarized. Also, 
for each specific outcome, we explored the possibility of 
performing meta‐analysis. Meta‐analysis could be per-
formed if (a) two or more studies within a DOAC strata 
reported on a specific outcome and (b) the between‐study 
statistical heterogeneity was below 65% as expressed by 
the I2‐statistics.23 If fulfilled, we combined point esti-
mates to calculate the pooled weighted estimate of the 
outcome in VKA‐experienced users of DOAC vs VKA 
using a random‐effect model based on the inverse vari-
ance method.24
2.5 | Other
The study was conducted in accordance with the Basic & 
Clinical Pharmacology & Toxicology policy for experimen-
tal and clinical studies.25 All analyses were performed using 
Stata Release 15.0 (StataCorp).
3 |  RESULTS
Our search strategy yielded 1751 potentially relevant stud-
ies (Figure 1). After exclusion of 410 duplicates, 1341 titles 
and abstracts were assessed for eligibility. A total of 24 origi-
nal articles were selected for full‐text review, of which eight 
studies fulfilled the criteria for inclusion in the systematic 
review.26-33 Reasons for exclusions for the other 16 studies 
are specified in Table S3.
F I G U R E  1  Flow chart of the study 
selection
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3.1 | Characteristics of the included studies
Characteristics and methodological details of the included 
studies are provided in Table 1 and Table S4, respectively. 
All included studies were observational cohort studies ex-
ploring the comparative effectiveness and/or safety of da-
bigatran or rivaroxaban and VKA in VKA‐experienced AF 
patients. Warfarin was the only studied VKA in all but one 
study that also included fluindione and acenocoumarol.26 
The studies were heterogeneous with regard to several 
methodological characteristics. The definition of VKA ex-
perience, and thereby likely also the proportion of DOAC 
initiators switched directly from VKA, varied between the 
included studies (Table S4). Duration of follow‐up was 
reported differently across studies and varied from ‘up to 
four months’ in Sørensen et al to a median follow‐up of 
15 months (interquartile range not provided) in Bengtson 
et al.27,28
In all studies, the risk of bias was assessed to be either low 
or moderate, with a range of 6‐9 points and a mean score of 
7.3 (Table S5). The items leading to risk of bias were similar 
across studies with the most common reasons being that the 
study was performed in a subgroup of AF patients, did not 
consider incident outcomes only and/or did not account for 
the quality of VKA therapy before or after start of follow‐up.
The results for the individual outcomes in VKA‐experi-
enced users can be found for dabigatran in Figure 2 and for 
rivaroxaban in Figure 3. Of note, some of the included studies 
provided stratified risk estimates only (stratified by DOAC 
dose or type, specified in Table 1) and could therefore con-
tribute with more than one estimate in a combined analysis.
3.2 | Comparative effectiveness of DOAC vs. 
VKA in VKA‐experienced AF patients
With the exception of the high rate of ischaemic stroke reported 
for AF patients using oral anticoagulants for secondary preven-
tion in Larsen et al,29 crude incidence rates for arterial thrombo-
embolic outcomes only varied slightly between studies (Table 
S6). Most studies reporting on the risk of ischaemic stroke for 
F I G U R E  2  Dabigatran vs VKA. Risk of arterial thromboembolism and bleeding for dabigatran vs VKA in VKA‐experienced oral 
anticoagulant users with atrial fibrillation. Abbreviations: CI, confidence interval; DOAC, direct oral anticoagulant; VKA, vitamin K antagonist. 
* The ischaemic stroke outcome was based on studies reporting ischaemic stroke alone or in combination with transient ischaemic attack and/or 
systemic embolism. The conditions included in the outcome in each of the studies are specified in Table 1
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dabigatran vs VKA in VKA‐experienced users found either no 
or a slightly increased risk. As the only study, Sørensen et al 
found a substantially increased risk. The meta‐analysis yielded 
a combined adjusted HR of the ischaemic stroke risk in VKA‐
experienced dabigatran initiators of 1.61 (95% confidence in-
terval [CI] 1.19‐2.19, I2 = 65%) when compared to continued 
VKA use. Also, the risk of myocardial infarction was slightly 
increased among VKA‐experienced dabigatran users compared 
to continued VKA users in all studies reporting on this outcome 
(pooled adjusted HR 1.29; 95% CI 1.10‐1.52, I2 = 0%). Both 
studies reporting on the risk of arterial thromboembolic events 
in VKA‐experienced rivaroxaban initiators found no increased 
risk of either ischaemic stroke (pooled adjusted HR 1.02; 95% 
CI 0.81‐1.28, I2  =  0%) or myocardial infarction (pooled ad-
justed HR 1.02; 0.78‐1.32, I2 = 8%) when compared to contin-
ued VKA users.
3.3 | Comparative safety of DOAC vs VKA 
in VKA‐experienced AF patients
Crude incidence rates for any bleeding and gastrointes-
tinal bleeding varied markedly between studies with the 
highest rates reported in the studies by Sørensen et al and 
Sarrazin et al (Table S6).27,30 Intracranial bleeding rates 
were low in all study cohorts (0.20‐0.69/100 person‐years 
and 0.21‐0.71/100 person‐years in DOAC and VKA co-
horts, respectively). Meta‐analysis could be allowed 
only for the comparative safety of dabigatran vs VKA in 
VKA‐experienced users for the outcomes gastrointestinal 
bleeding and intracranial bleeding. The studies reporting 
on the comparative risk of any bleeding in VKA‐experi-
enced users showed point estimates close to 1.0 with 95% 
CIs overlapping or almost overlapping unity irrespective 
of DOAC type. The only exception was the subgroup of 
VKA‐experienced patients on reduced dose dabigatran in 
Sørensen et al,27 for whom there was an adjusted pooled 
HR for any bleeding of 3.30 (95% CI 2.40‐4.53) compared 
to continuous VKA users. Also, the risk of gastrointestinal 
bleeding was higher in VKA‐experienced dabigatran users 
than in patients kept on VKA therapy (pooled adjusted HR 
1.63; 95% CI 1.36‐1.94, I2 = 30%). A similar association 
was found for rivaroxaban in Norby et al (HR 1.55; 95% CI 
1.32‐1.83).33 The risk of intracranial bleeding was reduced 
in VKA‐experienced users of dabigatran (pooled adjusted 
HR of 0.45; 95% CI 0.32‐0.64, I2 = 0%), but not rivaroxa-
ban (HR 1.04; 95% CI 0.66‐1.65 in Norby et al),33 when 
compared to continued VKA users.
All‐cause mortality in VKA‐experienced oral anticoagu-
lant users was only reported in the study by Sarrazin et al,30 
which found an odds ratio of 0.76 (95% CI 0.49‐1.17) when 
F I G U R E  3  Rivaroxaban vs VKA. Risk of arterial thromboembolism and bleeding for rivaroxaban vs VKA in VKA‐experienced oral 
anticoagulant users with atrial fibrillation. Abbreviations: CI, confidence interval; DOAC, direct oral anticoagulant VKA, vitamin K antagonist. 
* The ischaemic stroke outcome was based on studies reporting ischaemic stroke alone or in combination with transient ischaemic attack and/or 
systemic embolism. The conditions included in the outcome in each of the studies are specified in Table 1
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comparing VKA‐experienced dabigatran users to continued 
VKA users.
4 |  DISCUSSION
This systematic review and meta‐analysis of observational 
studies of VKA‐experienced AF patients had three main 
findings concerning the effectiveness and safety of DOAC 
therapy when compared to continued VKA use. Firstly, the 
use of dabigatran, but not rivaroxaban, was associated with 
an increased risk of arterial thromboembolism. Secondly, 
prior VKA users switched to dabigatran or rivaroxaban had 
an increased risk of gastrointestinal bleeding. Thirdly, the 
risk of intracranial bleeding was lower in VKA‐experienced 
dabigatran users than in continued VKA users.
Some limitations should be addressed. Firstly, this meta‐
analysis was based on observational evidence alone and is 
susceptible to the limitations inherent to this type of research 
most importantly the potential for confounding. As an exam-
ple, only few of the included studies had information on the 
quality of VKA therapy in study participants, which could 
thereby not be accounted for in their analyses. Secondly, the 
validity of the pooled estimates of the meta‐analyses may 
be limited by important clinical and methodological differ-
ences between studies as well as by the risk of duplicate data. 
Several of the included studies were based on Danish AF pa-
tients. Although these studies focused on different subgroups 
of patients, different outcomes, and had different study peri-
ods, this might have given Danish observations undue weight. 
Thirdly, the risk of switching‐related complications is highly 
depended on the transition regimen employed.34 As such, dif-
ferences between study results could, in part, be explained by 
varying compliance with the recommended switching proce-
dures. However, none of the studies included in the present 
systematic review and meta‐analysis provided information on 
this issue. Finally, as most studies were on dabigatran and 
performed in Western Europe or the United States, general-
ization of our findings to other DOACs and to populations 
with other demographics and standards of care, including an-
ticoagulant control,35 should be made with caution.
As the only study, Sørensen et al found use of dabiga-
tran in VKA‐experienced users to be associated with a mark-
edly higher risk of ischaemic stroke than continued use of 
VKA.27 Although the contribution of this ‘outlier’ study 
to the meta‐analysis was limited due to the low number of 
events, the pooled estimate for the ischaemic stroke outcome 
should be interpreted with caution. The higher risk in this 
specific study could be due to chance. Alternatively, it could 
also be explained by the study being based on the very first 
months of dabigatran use following market entry. Studies 
based on this period alone are likely especially susceptible 
to bias due to channelling of dabigatran to frail or high‐risk 
patients who have previously failed or been found unsuitable 
for VKA therapy.36 Further supporting the presence of re-
sidual confounding by frailty in the study is the finding of 
a higher bleeding risk in dabigatran users on reduced dose 
than on standard dose, which contrasts with RCT findings 1 
as well as with pharmacological reasoning. Also, as the study 
by Sørensen et al had the shortest follow‐up time (‘up to four 
months’) of all the included studies, their results could re-
flect an increased risk of complications in the early period 
following oral anticoagulant switching corresponding to the 
observations immediately after start and termination of the 
DOAC trials.34,37-40 Such potential early risks may be out-
weighed by potential benefits of DOAC use over time, which 
could explain that the associations receded towards unity in 
studies with longer follow‐up. Unfortunately, the low number 
of included studies did not allow us to meaningfully explore 
this issue further.
For most outcomes, there was agreement between 
our findings and the results concerning VKA‐experi-
enced patients in the randomized controlled trials RELY 
(Randomized Evaluation of Long‐Term Anticoagulation 
Therapy) and ROCKET AF (Rivaroxaban Once‐Daily, 
Oral, Direct Factor Xa Inhibition Compared With Vitamin 
K Antagonism for Prevention of Stroke and Embolism 
Trial in Atrial Fibrillation) (the results of these subgroup 
analyses are provided for context in Figure 4).8,9 However, 
while dabigatran reduced the risk of ischaemic stroke and 
systemic embolism in the VKA‐experienced stratum of 
RELY,8 none of the studies included in our review were 
able to confirm this trial finding in a real‐world setting. In 
all studies, the risk of ischaemic stroke was higher among 
VKA‐experienced dabigatran users than among patients 
staying on VKA. A similar discrepancy was, however, not 
observed between the rivaroxaban strata of our systematic 
review and meta‐analysis and the results from ROCKET 
AF.9 Although our finding may reflect a true difference in 
the relative stroke risk in VKA‐experienced users accord-
ing to study setting and DOAC type, the collective findings 
could also be explained by other mechanisms. We propose 
two such alternative interpretations. Firstly, consistent with 
prior reports on the adherence to DOACs in real‐world pa-
tients,41 our findings could reflect suboptimal adherence 
to especially dabigatran in clinical practice. A second pos-
sible explanation is the selection performed by physicians 
in clinical practice when choosing to switch some VKA‐
treated patients to DOAC and others to stay on VKA. In the 
Dresden non‐VKA oral anticoagulants Registry,42 patients 
maintained on VKA therapy were less likely than patients 
switched to DOAC to have a history of stroke and unstable 
INRs, both of which are important predictors of stroke on 
VKA therapy.43 This clinical selection process therefore 
channels VKA users likely to perform poorly on VKA to 
the DOAC group (ie the exposed group in observational 
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studies) and users likely to perform well on VKA therapy 
to the VKA group (ie the comparator group). Supportive 
of this explanation is the fact that the rates of ischaemic 
stroke among continued VKA users in the included obser-
vational studies (Table S6) were consistently lower than 
the corresponding rates in VKA‐experienced trial partic-
ipants in the warfarin arm (0.45/100PY‐1.15/100PY vs 
1.47/100 PY‐2.09/100PY). The observed association be-
tween switching from VKA to dabigatran and risk of isch-
aemic stroke may reflect a low stroke risk among patients 
selected to stay on VKA therapy rather than an increased 
stroke risk following switching to dabigatran. Importantly, 
if such selective prescribing (or, more precisely, selective 
switching) is an important driver of our results, it would 
not be appropriate to conclude on differences in treatment 
effect between groups due to the risk of residual confound-
ing. The rivaroxaban strata of our meta‐analysis were over-
all in accordance with the results from ROCKET AF.9 A 
potential explanation of the inconsistent findings between 
dabigatran and rivaroxaban may be that the study contribut-
ing with the highest number of switchers to rivaroxaban 33  
had the highest degree of confounder control of all in-
cluded studies.
If a high quality of VKA therapy in the comparison groups 
of the included studies is indeed the explanation of our find-
ings of an increased risk of ischaemic stroke in switchers 
from VKA to DOAC, they can be viewed as consistent with 
the TTR (ie time spent in the therapeutic interval) stratified 
results of RELY. These demonstrated that a high quality of 
VKA therapy reduces the efficacy benefit of dabigatran vs 
VKA, whereas the lower risk of intracranial bleeding is con-
sistent across levels of TTR.35 As guidelines support switch-
ing from VKA to DOAC at TTR levels below 70%,44 it seems 
likely that patients kept on VKA therapy, despite the avail-
ability of DOACs, would perform well on VKA therapy, as 
observed in the included studies. As such, we consider our 
F I G U R E  4  VKA‐experienced strata of the randomized clinical trials. Forest plots and meta‐analyses (if I2 ≤ 65%) of the risk of arterial 
thromboembolism, bleeding, and all‐cause mortality in the VKA‐experienced strata of the randomized clinical trials comparing DOAC to VKA 
in patients with atrial fibrillation. Abbreviations: CI, confidence interval; DOAC, direct oral anticoagulant; VKA, vitamin K antagonist; RELY, 
Randomized Evaluation of Long‐Term Anticoagulation Therapy; ROCKET AF, Rivaroxaban Once‐Daily, Oral, Direct Factor Xa Inhibition 
Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; ARISTOTLE, Apixaban for Reduction 
in Stroke and Other Thromboembolic Events in Atrial Fibrillation; ENGAGE AF, Effective Anticoagulation with Factor Xa Next Generation in 
Atrial Fibrillation
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results concerning AF patients staying on VKA as overall 
reassuring and supportive of the selection performed by phy-
sicians when choosing which patients should not be switched 
to DOAC therapy in clinical practice. Also, in a recent small 
Dutch RCT,45 AF patients with high TTR levels on VKA 
therapy randomized to continued VKA therapy had compa-
rable 1‐year risks of arterial thromboembolism and bleeding 
to patients randomized to switch to a DOAC (mainly apix-
aban). Thus, this trial, as well as the results of the current 
review, supports that a satisfactory effectiveness and safety of 
oral anticoagulant therapy can likely be expected if choosing 
to continue VKA in AF patients presenting with high TTR 
levels.
Despite searching for references published up until 
October 2018, no eligible studies addressing the comparative 
effectiveness and/or safety of neither apixaban nor edoxaban 
vs. VKA in VKA‐experienced AF patients were identified. 
Although these drugs had a later market entry than dabiga-
tran and rivaroxaban, the use of especially apixaban among 
AF patients is extensive.6,46,47 Further, in a recent register‐
based drug utilization study, we showed that 16% of all AF 
patients initiating apixaban during the period of June 2016 to 
June 2017 in Denmark switched directly from VKA.48 In the 
VKA‐experienced stratum of the ARISTOTLE (Apixaban for 
Reduction in Stroke and Other Thromboembolic Events in 
Atrial Fibrillation) trial, the risks of ischaemic stroke, major 
bleeding and intracranial bleeding were significantly lower in 
the apixaban arm than in the warfarin arm.10 Although these 
results are reassuring, patients using apixaban may be espe-
cially susceptible to switching‐related risks, as apixaban has 
become the preferred anticoagulant among the eldest, most 
frail and comorbid AF patients.49,50 Thus, studies explor-
ing the risks and benefits associated with use of apixaban 
in VKA‐experienced patients in clinical practice including 
switching from VKA to apixaban are highly warranted.
4.1 | Conclusion
Consistent with trial findings, the use of DOAC in VKA‐
experienced AF patients from everyday clinical settings 
was associated with a lower risk of intracranial bleed-
ing (dabigatran) and an increased risk of gastrointestinal 
bleeding (dabigatran and rivaroxaban) when compared to 
patients kept on VKA. In contrast with trial findings, obser-
vational studies did not support that switching from VKA 
to dabigatran is associated with a lower risk of ischaemic 
stroke than non‐switch. Whether this reflects an excess risk 
of events in VKA‐experienced dabigatran users/switchers 
from VKA to dabigatran or rather that patients staying on 
VKA therapy in clinical practice have a low risk of ischae-
mic stroke needs to be explored further. In future studies, 
special attention needs to be paid to potential confound-
ing from the underlying reasons for switching to DOAC 
therapy or not, which have likely affected the results of 
current observational studies.
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